TEVA

Teva Pharmaceutical Indu... (TEVA)

Teva Pharmaceutical Industries Ltd

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NYSE:TEVA

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/21	09 : 25	GlobeNewswire Inc.	Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/05/21	09 : 25	Business Wire	Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/05/15	21 : 36	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/05/15	21 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/05/15	21 : 15	Business Wire	Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/05/09	20 : 53	IH Market News	Bain Capital in Talks to Acquire PowerSchool; Blackstone Emerges Victorious in Hipgnosis Bidding War, and More News	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/05/08	20 : 00	Business Wire	Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/05/08	19 : 30	Business Wire	Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/05/03	07 : 30	Business Wire	Teva to Present at the 2024 Bank of America Healthcare Conference	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/05/02	21 : 30	Business Wire	Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/04/30	17 : 00	Business Wire	U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/04/30	17 : 00	GlobeNewswire Inc.	U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/04/17	06 : 43	Business Wire	Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/04/17	06 : 30	GlobeNewswire Inc.	Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/04/16	21 : 00	Business Wire	Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/04/11	21 : 30	Business Wire	Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/04/10	05 : 30	Business Wire	Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/04/07	02 : 00	Business Wire	New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/04/04	21 : 30	Business Wire	Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/04/01	21 : 30	Business Wire	Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/03/08	06 : 27	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/03/08	06 : 24	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/03/08	06 : 20	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/03/08	06 : 16	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/03/08	06 : 12	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/03/08	06 : 08	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/03/06	06 : 46	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/03/06	06 : 43	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/03/06	06 : 39	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
2024/03/06	06 : 35	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:TEVA	Teva Pharmaceutical Industries Ltd